Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trimethoprim-sulfamethoxazole.

J D Smilack1

  • 1Division of Infectious Diseases, Mayo Clinic Scottsdale, Arizona.

Mayo Clinic Proceedings
|July 16, 1999
PubMed
Summary
This summary is machine-generated.

Trimethoprim-sulfamethoxazole (TMP-SMX) effectively inhibits common pathogens by blocking folic acid synthesis. However, increasing resistance and side effects may limit its future use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gastrointestinal basidiobolomycosis in Arizona: clinical and epidemiological characteristics and review of the literature.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Colonic perforation in unsuspected amebic colitis.

Digestive diseases and sciences·2000
Same author

Ventral hernia synthetic mesh repair infected by Mycobacterium fortuitum.

The American surgeon·1999
Same author

Gastrointestinal basidiobolomycosis. Morphologic findings in a cluster of six cases.

American journal of clinical pathology·1999
Same author

Images in clinical medicine. Pulmonary and disseminated nocardiosis.

The New England journal of medicine·1999
Same author

The tetracyclines.

Mayo Clinic proceedings·1999
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Trimethoprim-sulfamethoxazole (TMP-SMX) has been widely used for 25 years in the United States.
  • It targets microbial folic acid synthesis, showing broad in vitro activity against common pathogens.

Purpose of the Study:

  • To review the efficacy and limitations of TMP-SMX.
  • To discuss its use in specific patient populations and emerging challenges.

Main Methods:

  • Review of existing literature on TMP-SMX.
  • Analysis of its mechanism of action, clinical applications, and adverse effects.

Main Results:

  • TMP-SMX demonstrates potent activity against respiratory, urinary tract, and nosocomial pathogens.

Related Experiment Videos

  • It is effective for Pneumocystis carinii prophylaxis/treatment in HIV patients, despite side effects.
  • Established uses include nocardiosis, Wegener's granulomatosis, and bacterial peritonitis prophylaxis.

    • Conclusions:

    • TMP-SMX remains a valuable antimicrobial agent for various infections.
    • Concerns regarding increasing bacterial resistance and adverse effects warrant careful consideration for its future utility.